Clinical trials: Bone Marrow
Paroxysmal Nocturnal Hemoglobinuria
REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.
The primary objective of the study is to evaluate the long-term safety, tolerability, and effect on intravascular hemolysis of REGN3918 in patients with paroxysmal nocturnal hemoglobinuria (PNH).
- Trial name
- NCT04162470
- Testing
- REGN3918
- Where
- 14 sites in Hong Kong, Hungary and 4 more
- Volunteers
- 24 people
- Sponsor
- Regeneron Pharmaceuticals
Avascular Necrosis of the Femoral Head
Bone Marrow Cells With Core Decompression for AVN Treatment
Avascular necrosis of the femoral head (AVN) is a progressive pathological process resulting from disruption of blood supply to the femoral head and elevation of intraosseous pressure.
- Trial name
- NCT05982054
- Testing
- core decompression with local bone marrow mononuclear cells injection
- Where
- Iraq
- Volunteers
- 10 people
- Sponsor
- Global Stem Cell Center, Baghdad
AML, ALL
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic…
- Conditions
- AML, ALL, MDS, MPD Withou Myelofibrosis
- Trial name
- NCT04644016
- Testing
- Clofarabine, Fludarabine, Busulfan
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myelodysplastic Syndrome
Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome
This is a Phase 1 clinical trial to evaluate the tolerability of a combination therapy of SyB C-1101 (rigosertib sodium) and Azacytidine and to determine the recommended dose of SyB C-1101for Phase 2 trial in patients with…
- Trial name
- NCT02783547
- Testing
- SyB C-1101 and Azacytidine
- Where
- 4 sites in Japan
- Sponsor
- SymBio Pharmaceuticals
Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation
Pediatric GVHD Low Risk Steroid Taper Trial
The standard treatment for acute graft-vs-host disease (GVHD) is to suppress the activity of the donor immune cells using steroid medications such as prednisone.
- Conditions
- Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
- Trial name
- NCT05090384
- Testing
- Prednisone
- Where
- 11 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- John Levine
Myelofibrosis
To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects
TQ05105 is a class 1 new drug with a new chemical structure developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. It is a Janus Kinase 2 （JAK2）inhibitor and can be used to treat JAK2 target-related diseases.
- Trial name
- NCT05982106
- Testing
- TQ05105 Tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Leukemia, Lung Cancer
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop cancer cells from…
- Conditions
- Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes
- Trial name
- NCT00398138
- Testing
- WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myelodysplastic Syndromes
Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.
The is a phase 2, single-arm, open-label clinical study assessing the efficacy and safety of hetrombopag to increase platelet count in lower-risk MDS patients with thrombocytopenia.
- Trial name
- NCT05392647
- Testing
- Hetrombopag
- Volunteers
- 28 people
- Sponsor
- Tongji Hospital
Leukemia
Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- AML1107 (NCT00775593)
- Testing
- clofarabine, temsirolimus
- Where
- 19 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
This study will be divided into two parts, Parts A and B and will enroll patients with relapsed/refractory AML or MDS/chronic myelomonocytic leukemia (CMML) patients who have failed up to 2 prior therapeutic regimens.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
- Trial name
- NCT04937166
- Testing
- DSP107, Azacitidine, Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Kahr Medical
Colorectal Cancer (CRC), Specimens Are to be Collected From Subjects Who Are Having or Have Had a Fluid or Tissue Removed, a Biopsy or a Blood or Bone Marrow Draw
CYFIP1 and PKM2 Synergistically Regulate ROS and Glycolysis in Colorectal Cancer Through the AKT/mTOR/HIF-1α Cascad
Collect some tumor tissue specimens from patients who have undergone colorectal cancer surgery and conduct experiments such as immunohistochemistry to observe the expression of related genes in colorectal cancer.
- Trial name
- NCT07197151
- Testing
- Perform surgery on patients with colorectal cancer and collect cancer and adjacent tissue specimens
- Where
- China
- Volunteers
- 32 people
- Sponsor
- hui hou
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL
This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.
- Trial name
- NCT00384228
- Testing
- Nilotinib
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia
Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia
Primary objective: To determine overall response-rate, complete response (CR) or partial response (PR) Secondary objectives: To assess the safety and tolerability of ITF2357; to assess total rate of responders (complete + partial…
- Trial name
- NCT00792831
- Testing
- ITF2357
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Italfarmaco
Graft Vs Host Disease, Inflammatory Bowel Diseases
Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial)
The goal of the Precision Diagnosis in Inflammatory Bowel Disease, Cellular Therapies, and Transplantation (PREDICT) trial is to apply a systems-biology approach to enable precision diagnostics for the key immunologic outcomes…
- Conditions
- Graft Vs Host Disease, Inflammatory Bowel Diseases, Functional Gastrointestinal Disorders
- Trial name
- PREDICT (NCT03369353)
- Where
- 4 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Boston Children's Hospital
Myelodysplastic Syndrome
An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)
The purpose of this study is to evaluate the response rate of decitabine in previously treated and untreated Taiwanese participants with Myelodysplastic Syndrome (MDS - a disease associated with decreased production of blood…
- Trial name
- NCT00744757
- Testing
- Decitabine
- Where
- 6 sites in Taiwan
- Volunteers
- 37 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Idiopathic Interstitial Pneumonia, Interstitial Lung Disease
Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease
The study evaluates the safety and the efficacy of the addition of intravenous transplantation of donor bone marrow mesenchymal stem cells in patients with idiopathic interstitial pneumonia or connective tissue disease associated…
- Conditions
- Idiopathic Interstitial Pneumonia, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT02594839
- Testing
- Bone marrow mesenchymal stem cells
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
Anemia, Aplastic, Blood Disease
Etiology of Blood Dyscrasias: Analysis of the International Agranulocytosis and Aplastic Anemia Study Data
To quantify the role of drugs and other factors in the etiology of agranulocytosis and aplastic anemia.
- Conditions
- Anemia, Aplastic, Blood Disease, Agranulocytosis
- Trial name
- NCT00005307
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Primary Myelofibrosis, Secondary Myelofibrosis
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
This phase II trial studies how well administering ruxolitinib before, during, and after allogeneic hematopoietic stem cell transplantation works in preventing graft versus host disease and improving transplant outcomes in…
- Trial name
- NCT04384692
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Aplastic Anemias
Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study
Aplastic anemia (AA) is a rare bone marrow failure syndrome with an annual incidence of about 0.74/100,000, affecting all ages but more common in the elderly.
- Trial name
- NCT06650553
- Testing
- Clinically diagnosed AA patients are divided into HLA-matched HSCT group and umbilical cord blood-supported haplo-HSCT group.
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Shanxi Bethune Hospital
Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Medication Adherence
Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients
Owing to effective treatment with tyrosine kinase inhibitors (TKIs), chronic myeloid leukemia (CML) has become a chronic disease with a rising prevalence globally.
- Trial name
- NCT03090477
- Testing
- Pharmaceutical care and adherence aids
- Where
- 2 sites in Malaysia
- Volunteers
- 129 people
- Sponsor
- UCSI University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.